Sanodyne Therapeutics, Inc., one of our portfolio companies, was selected for AMED Strengthening Program for Pharmaceutical Venture Ecosystem

Feb 25, 2026 — Sanodyne Therapeutics, Inc., one of our portfolio companies in Japan, was selected as one of the supported projects in “Strengthening Program for Pharmaceutical Venture Ecosystem (11th call)” by Japan Agency for Medical Research and Development (AMED).

https://www.amed.go.jp/koubo/03008/01/C_00002.html

In this program, AMED provides matching financial support for the drug development of selected projects on the condition that an equity investment is executed by an AMED accredited venture capital firm that provides hands-on support focusing on drug discovery and development. Remiges Venures/RDiscovery was selected as one of the accredited venture capital firms in 2022.

Sanodyne Therapeutics is developing an innovative small-molecule drug candidate, SNT-001, which has the potential to be a disease-modifying drug in peripheral neuropathy and neuropathic pain, originated by Toray, Inc.

RDiscovery supports Sanodyne’s technology and business development through its participation in the Board of Directors meetings and other activities to increase the value of the lead program, an innovation originating in Japan.